Eisai将向公司支付：(a) 首付款7500万美元，于许可协议订立后支付; (b) 监管里程碑款项合计至多8001 万美元，基于许可产品于区域内的各项监管里程碑达成情况支付; (c) 商业销售里程碑款项合计至多约 2.33亿美元，基于许可产品于区域内的年度净销售额水平达成情况支付;及 (d) 以许可产品于区域内的年 度净销售额的两位数百分比计的特许权使用费。 据悉，汉斯状® (斯鲁利单抗注射液)为公司自主开发的创新型抗PD-1单抗，其于中国境内(不包括中国 港澳台地区，下同)已获批上市的适应症包括联合化疗一线治疗鳞状非小细胞肺癌(sq-NSCLC)、广泛期 小细胞肺癌(ES-SCLC)、食管鳞状细胞癌(ESCC)及非鳞状非小细胞肺癌(nsq-NSCLC)。同时，汉斯状® 亦已分别于欧盟、英国、印度尼西亚、柬埔寨、泰国、马来西亚、新加坡、及印度等国家/地区获批上 市，并分别获美国、欧盟、瑞士及韩国等国家/地区的药品监督管理部门授予孤儿药资格认定。此外， 公司正有序推进汉斯状® 及相关联合疗法在全球开展的多项临床试验，广泛覆盖肺癌、食管癌、头颈 鳞癌、结直肠癌和胃癌等适应症。2025年12月，汉斯状®联合化疗于 ...

Eisai将向公司支付：(a)首付款7500万美元，于许可协议订立后支付;(b)监管里程碑款项合计至多8001万 美元，基于许可产品于区域内的各项监管里程碑达成情况支付;(c)商业销售里程碑款项合计至多约2.33 亿美元，基于许可产品于区域内的年度净销售额水平达成情况支付;及(d)以许可产品于区域内的年度净 销售额的两位数百分比计的特许权使用费。 本次与Eisai就许可产品于区域内的商业化合作将有助于进一步拓展公司产品的海外市场，增强公司产品 在国际市场的可及性和认可度，从而为公司收入的持续提升创造条件。 复宏汉霖(02696)公布，公司于2026年2月5日与Eisai Co.,Ltd.(Eisai)订立一份许可协议，据此，公司同意 向Eisai授出一项许可，供其于日本及领域内开发、生产和商业化汉斯状(斯鲁利单抗注射液)。许可产品 用于肿瘤适应症的治疗。 据悉，汉斯状(斯鲁利单抗注射液)为公司自主开发的创新型抗PD-1单抗，其于中国境内(不包括中国港 澳台地区，下同)已获批上市的适应症包括联合化疗一线治疗鳞状非小细胞肺癌(sq-NSCLC)、广泛期小 细胞肺癌(ES-SCLC)、食管鳞状细胞癌(ESCC)及非 ...

据悉，汉斯状® (斯鲁利单抗注射液)为公司自主开发的创新型抗PD-1单抗，其于中国境内(不包括中国 港澳台地区，下同)已获批上市的适应症包括联合化疗一线治疗鳞状非小细胞肺癌(sq-NSCLC)、广泛期 小细胞肺癌(ES-SCLC)、食管鳞状细胞癌(ESCC)及非鳞状非小细胞肺癌(nsq-NSCLC)。同时，汉斯状® 亦已分别于欧盟、英国、印度尼西亚、柬埔寨、泰国、马来西亚、新加坡、及印度等国家/地区获批上 市，并分别获美国、欧盟、瑞士及韩国等国家/地区的药品监督管理部门授予孤儿药资格认定。此外， 公司正有序推进汉斯状® 及相关联合疗法在全球开展的多项临床试验，广泛覆盖肺癌、食管癌、头颈 鳞癌、结直肠癌和胃癌等适应症。2025年12月，汉斯状®联合化疗于胃癌新辅助/辅助治疗的药品注册 申请获国家药品监督管理局(NMPA)受理，并已纳入优先审评审批程序。 本次与Eisai就许可产品于区域内的商业化合作将有助于进一步拓展公司产品的海外市场，增强公司产品 在国际市场的可及性和认可度，从而为公司收入的持续提升创造条件。 智通财经APP讯，复宏汉霖(02696)公布，公司于2026年2月5日与Eisai Co., Ltd ...

格隆汇2月5日丨复宏汉霖(02696.HK)宣布，公司于2026年2月5日与Eisai Co., Ltd.("Eisai")订立一份许可 协议，据此，公司同意向Eisai授出一项许可，供其于日本("区域")及领域(定义如下文)内开发、生产和 商业化汉斯状®(斯鲁利单抗注射液)("许可产品")。 本次与Eisai就许可产品于区域内的商业化合作将有助于进一步拓展公司产品的海外市场，增强公司产品 在国际市场的可及性和认可度，从而为公司收入的持续提升创造条件。 汉斯状®在中国境内的销售推广由公司自建商业化团队主导。截至公告日期，公司已分别与多个国际知 名合作伙伴就汉斯状®于全球超100个国家和地区的商业化达成合作。 根据许可协议，公司将授予Eisai：(a) 一项独家许可，供其于区域及领域内商业化许可产品；及(b) 仅就 上文(a)项所述目的，于区域及领域内开发和生产许可产品的共同排他许可(即公司亦有权开发和生产)。 Eisai将向公司支付：(a) 首付款7500万美元，于许可协议订立后支付；(b) 监管里程碑款项合计至多8001 万美元，基于许可产品于区域内的各项监管里程碑达成情况支付；(c) 商业销售里程碑款项合 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 內幕消息公告 就漢斯狀®與EISAI訂立的許可協議 A. 緒言 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第571章證券及 期貨條例第XIVA部之內幕消息條文（定義見上市規則）而作出。 本公司董事會欣然宣佈，本公司於2026年2月5日與Eisai Co., Ltd.（「Eisai」） 訂立一份許可協議（「許可協議」），據此，本公司同意向Eisai授出一項許可， 供其於日本（「區域」）及領域（定義如下文）內開發、生產和商業化漢斯狀® （斯魯利單抗注射液）（「許可產品」）。 B. 許可協議的主要條款 許可事項 本公司將授予Eisai： 領域 許可產品用於腫瘤適應症的治療。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技 ...

Core Viewpoint - The Hong Kong biotechnology sector is experiencing a significant upward trend, with notable gains in various stocks, indicating positive market sentiment in the industry [1] Group 1: Stock Performance - Nocare Biopharma (09969.HK) has seen an increase of over 4% [1] - Other companies such as Zai Lab (09688.HK), WuXi AppTec (02359.HK), WuXi Biologics (02269.HK), and Innovent Biologics (02696.HK) are also witnessing upward movement in their stock prices [1]

Group 1 - JD.com (SWR 89618) has the highest short-selling ratio at 85.52%, followed by AIA Group (R 81299) at 77.11% and Lenovo Group (R 80992) at 67.79% [1][2] - Tencent Holdings (00700) leads in short-selling amount with 2.709 billion yuan, followed by Pop Mart (09992) at 974 million yuan and Xiaomi Group (W 01810) at 793 million yuan [1][2] - Huatai Securities (06886) has the highest deviation value at 40.23%, followed by Tong Ren Tang Technologies (01666) at 35.46% and China Ship Leasing (03877) at 26.75% [1][2] Group 2 - The top ten short-selling ratios include JD.com at 85.52%, AIA Group at 77.11%, and Lenovo Group at 67.79% [2] - The top ten short-selling amounts show Tencent Holdings at 2.709 billion yuan, Pop Mart at 974 million yuan, and Xiaomi Group at 793 million yuan [2] - The top ten deviation values are led by Huatai Securities at 40.23%, followed by Tong Ren Tang Technologies at 35.46% and China Ship Leasing at 26.75% [2]

Core Viewpoint - The completion of the H-share full circulation by Fuhong Hanlin marks a significant step in the company's equity structure and capital operations, enhancing liquidity and governance standards while supporting its global strategy and innovation efforts [1] Group 1: H-share Full Circulation - A total of 183 million non-listed shares have been converted into H-shares, which will start trading on the Hong Kong Stock Exchange on February 5, 2026 [1] - After the full circulation, the total number of H-shares will increase to 346 million [1] - The full circulation is expected to attract more international investors, benefiting the long-term development of the company and its shareholders [1] Group 2: Product Portfolio and Market Presence - Fuhong Hanlin has 10 products approved for sale in over 60 markets globally [1] - The company has achieved significant milestones in major biopharmaceutical markets, with 4 products receiving FDA approval and 4 products obtaining EMA authorization [1] - The company has a diversified pipeline with over 50 early-stage molecules, demonstrating its commitment to high-quality research and development aligned with international standards [1]

Core Viewpoint - The completion of H-share full circulation by Fuhong Hanlin marks a significant step in the company's equity structure and capital operations, enhancing liquidity and governance standards while supporting its global strategy and innovation efforts [1] Group 1: H-share Full Circulation - A total of 183 million non-listed shares were converted into H-shares, which will begin trading on the Hong Kong Stock Exchange on February 5, 2026 [1] - Following the full circulation, the total number of H-shares will increase to 346 million [1] - The full circulation is expected to attract more international investors, benefiting the long-term development and shareholder interests of the company [1] Group 2: Product Portfolio and Market Presence - Fuhong Hanlin has 10 products approved for sale in over 60 markets globally [1] - The company has achieved significant milestones in major biopharmaceutical markets, with 4 products receiving FDA approval and 4 products obtaining EMA authorization [1] - The company has a diversified pipeline with over 50 early-stage molecules, demonstrating its commitment to high-quality research and development aligned with international standards [1]

Core Viewpoint - The completion of the H-share full circulation marks a significant step for the company in terms of equity structure and capital operations, enhancing liquidity and governance while supporting its global strategy and innovation efforts [1] Group 1: H-share Full Circulation - The company announced the conversion of 182,645,856 non-listed shares into H-shares, which will start trading on February 5, 2026, increasing the total number of H-shares to 346,074,397 [1] - This move is expected to expand the liquidity of the company's shares listed in Hong Kong and improve market pricing effectiveness and fairness [1] Group 2: Financial Performance and Strategic Development - The company became the first Hong Kong-listed innovative pharmaceutical company to achieve full-year profitability in 2023, driven by product sales [1] - The stable cash flow generated from biosimilars will support ongoing innovation and research and development, as the company transitions into a "Globalization 2.0" development phase characterized by capability building and innovation [1]